Trifluoperazine hydrochloride

盐酸三氟拉嗪

Report date: 2022/05/19 14:22:31
NME

Base Information

Drug NameTrifluoperazine hydrochloride
Drug Alias Nametrifluoperazina三氟拉嗪盐酸盐盐酸三氟啦嗪trifluoperazinumTrifluoroperazine hydrochloride +[11
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors antagonists
TargetsDopamine receptors
Therapy Area/IndicationsSchizophreniaAnxiety DisordersAnxiety +[4
Global Approved IndicationsSchizophreniaAnxiety DisordersAnxiety +[4
Approved Indications in ChinaSchizophreniaAnxietyDepression
Original Approved Country/TerritoryUnited States
Original Approved Date1959/04/16
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Inactive CompaniesGlaxosmithkline Plc
Active IndicationsSchizophreniaAnxietyDepression
Inactive IndicationsAnxiety Disorders

Other Information

ATC CodeN05AB06